Du forlater nå lundbeck.com/no

Denne lenken tar deg til en ny nettside. På nettsiden er det egne brukervilkår vedrørende innhold og koblinger som Lundbeck Norge ikke tar ansvar for.

 

Fortsett til nettside

Avbryt

Pipeline

Legemidler under utvikling

Våre forsknings- og utviklingsteam tar for seg de underliggende mekanismene til hjernesykdommer. Vi jobber sammen mot et felles mål om å levere nye og innovative behandlinger, som redefinerer standarden for behandling av pasienter og tar for seg de områdene innen hjernesykdommer hvor vi ser det største behovet.
Prosjekt Område Fase 1 Fase 2 Fase 3 Søknad
Eptinezumab (anti-CGRP mAb) Migraine prevention Filing

Virkningsmekanisme

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Eptinezumab (anti-CGRP mAb) Episodic cluster headache 3

Virkningsmekanisme

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Brexpiprazole* Agitation in Alzheimer's disease 3

Virkningsmekanisme

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Brexpiprazole* PTSD 3

Virkningsmekanisme

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonergic, dopaminergic, and especially the noradrenergic systems are believed to be involved in PTSD symptomatology with re-experiencing, Negative cognition and mood, Avoidance and Arousal.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Brexpiprazole* Borderline Personality DIsorder 2

Virkningsmekanisme

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. Serotonergic and Dopaminergic stabilization may directly address the pathways implicated in the BPD features of impulse aggression (SER), and emotional dysregulation, impulsivity, and cognitive disturbances (DA).

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Aripiprazole 2-month injectable* Schizophrenia + Bipolar I Disorder 1

Virkningsmekanisme

Aripiprazole is a small molecule. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonist at serotonin 5-HT2A receptors. A 2-month formulation will serve as a treatment option when treating patients with Schizophrenia or Bipolar I disorder where long-acting treatment is needed.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Lu AG06466 (MAGL inhibitor)* PTSD 1

Virkningsmekanisme

Lu AG06466 is a small molecule expected to be highly brain-penetrant. Lu AG06466 is a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing the actions of 2-AG may produce beneficial effects across a range of symptoms including stress, anxiety and hyperarousal; symptoms which are relevant to PTSD.

*MAGL: Monoacylglycerol lipase. PTSD study has been initiated, additional phase 1b studies within psychiatry/neurology will be explored during 2021.

Lu AG06479 (MAGL inhibitor)* Neurology, Psychiatry 1

Virkningsmekanisme

Lu AG06479 is a small molecule expected to be highly brain-penetrant. Lu AG06466 is a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing 2-AG levels is a viable approach to restore brain homeostasis.

*MAGL: Monoacylglycerol lipase. PTSD study has been initiated, additional phase 1b studies within psychiatry/neurology will be explored during 2021.

Lu AF82422 (alpha-synuclein mAb) Synucleinopathies 1

Virkningsmekanisme

Lu AF82422 is a monoclonal antibody targeting alpha-synuclein. Misfolding, aggregation and extracellular spreading of alpha-synuclein is believed to play a major role in disease pathology and progression in Parkinson’s disease and other neurodegenerative disorders.

Lu AF28996 (D1 D2 agonist) Parkinson's disease 1

Virkningsmekanisme

Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.

Lu AG09222 (PACAP mAb)* Migraine 1

Virkningsmekanisme

LU AG09222 is a monoclonal antibody designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP) signaling for migraine prevention. PACAP has emerged as a signaling molecule in the pathophysiology of migraine.

*PACAP: Pituitary adenylate cyclase-activating polypeptide

Lu AF87908 (Tau mAb) Tauopathies 1

Virkningsmekanisme

Lu AF87908 (Tau mAb) is a monoclonal antibody targeting the pathological form of the protein tau which is believed to play a pivotal role in the development and progression of Alzheimer’s disease and other neurodegenerative disorders.

Mer om Lundbeck

Forskning og Utvikling

FoU av nye og forbedrede behandinger er kjernen i det vi gjør.

Om oss

Et globalt farmasøytisk selskap som spesialiserer seg innen hjernesykdommer.

Forstå hjernesykdommer

Det første trinnet på ferden til god hjernehelse er å forstå hva som forårsaker hjernesykdommer.